Biomarker Testing in Non–Small Cell Lung Cancer

Opinion
Video

A panel of medical oncologists introduce themselves and provide clinical insights on biomarker testing practices for patients with non–small cell lung cancer.

Related Videos
Patients with NSCLC who have comorbidities or frailty may also be able to receive treatment with fewer toxicities via proton beam radiotherapy.
Terrence T. Sio, MD, MS, emphasizes multidisciplinary collaboration for treating patients with NSCLC who may require more than 1 type of therapy.
Video 2 - "MARIPOSA-2 Phase 3 Study Design and Treatment Arms"
Video 1 - "Background on Osimertinib Resistance Mechanisms and Unmet Needs Driving Evaluation of Novel Therapies"
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
video 8 - "Treatment Landscape for NSCLC With EGFR Exon 20 Insertion Mutations"
Video 7 - "Second-Line Treatment of Patients With EGFR-Mutated NSCLC"
Estelamari Rodriguez, MD, MPH, an expert on lung cancer
Christine Bestvina, MD, an expert on lung cancer
Related Content